《新股消息》昭衍新藥(06127.HK)公開發售超購309倍及上限定價 一手中籤率僅5%
昭衍新藥(06127.HK)公布招股結果,發售價定於151元,為上限定價(招股價介乎133元至151元),公開發售錄超購309倍,經重新分配後,公開發售股數增至36%。每手100股,中籤率為5%。該股將於明日(26日)上市。中信證券為獨家保薦人。
公司為上市引入11名基石投資者,包括Lake Bleu Prime、Orbimed基金、中國結構調整基金及CPE Fund等,合共認購1,375.98萬股股份,相當於緊隨全球發售完成後公司已發行股本約5.1%。
公司預計集資所得款項淨額約為62.86億元,當中16%將用於提高集團蘇州設施的服務能力;10%將用於增強集團美國業務以迎合客戶日益增長的對Biomere所提供服務的需求;39%將用於在廣州及重慶建設新設施;5%將用於拓展及深化集團綜合合同研究組織服務;20%將用於拓寬藥物研發價值鏈上的綜合服務範圍並拓展海外佈局的策略;以及10%為營運資金及一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.